子宫颈腺鳞癌21例临床分析  

Clinical analysis of 21 cases of cervical adenosquamous carcinoma

作　　者：蔡鸿宁[1] 吴绪峰[1] 向群英[1] 熊永炎[2] 曾俊[2] 

机构地区：[1]武汉大学中南医院妇瘤科,430071 [2]武汉大学中南医院病理科,430071

出　　处：《中华妇产科杂志》2008年第2期124-127,共4页Chinese Journal of Obstetrics and Gynecology

摘　　要：目的探讨宫颈腺鳞癌的临床特征、治疗模式及其对预后的影响。方法回顾性分析武汉大学中南医院2001年1月至2005年12月收治的21例宫颈腺鳞癌患者的临床资料。根据治疗方式的不同分为单纯手术治疗（6例）和综合治疗（15例），分析不同治疗模式对预后的影响。结果患者的中位年龄45岁，以未绝经患者（15例，占71％）为主；平均病程5．3个月（0．5—24．0个月），其中16例病程〈6个月；临床症状主要为阴道流血（17例，占81％）。21例患者中，盆腔淋巴结转移7例（33％），卵巢转移3例（14％）。21例患者的中位生存时间为54个月。其中，单纯手术治疗和综合治疗患者的中位生存时间分别为20、54个月，两者比较，差异无统计学意义（P〉0．05）。12例Ⅰb—Ⅱa期患者中，单纯手术治疗6例，综合治疗6例，其中位生存时间分别为20、66个月，两者比较，差异有统计学意义（P〈0．05）。结论宫颈腺鳞癌具有病程短、进展快、预后差的特点，应采取综合治疗措施，术中保留卵巢需谨慎。Objective To study the clinical characteristics, treatment modalities.and prognosis of cervical adenosquamous carcinoma. Methods The data of 21 patients with adenosquamous cervical cancer who were admitted into Zhongnan Hospital, Wuhan University from Jan 2001 to Dec 2005 were analyzed retrospectively. Six patients received surgical therapy only and 15 patients received combined therapy. Results Seven cases were with positive pelvic lymph node metastases and 3 cases were with ovarian metastases. The median survival time of the combined therapy group and surgical therapy group was 54 and 20 months, respectively. In stage Ⅰ and stage Ⅱ patients, the median survival time of the combined therapy group and surgical therapy group was 66 and 20 months, respectively. The difference was significant between the two groups （P 〈 0. 05 ） . Conclusions Combined therapy should be given to patients with adenosquamous carcinoma of the cervix. Surgical therapy and chemotherapy play an important role in the management and prognosis of adenoquamous carcinoma of cervix. Preserve of ovary for patients with adenosquamous carcinoma of the cervix should only be done when the ovary is confirmed free from any malignant involvement by pathology.

关 键 词：宫颈肿瘤 癌 腺鳞状 综合疗法 预后 

分 类 号：R686[医药卫生—骨科学]